Slide 1: FY2022 Second-Half Results Briefing Session - Financial Results
FY2022 Second-Half Results Briefing Session -Financial Results- May 12, 2023 JCR Pharmaceuticals Co., Ltd. 【Securities code】 4552, PRIME, TSE Copyright © 2023 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Slide 2: Financial Highlights (FY2022 Results)
Financial Highlights (FY2022 Results) Decrease in sales and profit due to decrease in license revenue and AZD1222 bulk solution manufacturing Net sales： 34,343 million yen, Year-on-year (32.8)％ Operating income： 4,975 million yen, YoY (75.0)％ Ordinary income： 5,418 million yen, YoY (73.6)％ Profit :
Slide 3: Consolidated Results
Consolidated Results （ Unit: million yen ） FY2022 FY2021 (Apr. 1, 2022-Mar. 31, 2023) Reference ◆Operating income 4,975 million yen Consolidated (Apr. 1, 2021- Year-on-year: (14,958) million yen Mar. 31, 2022) Year-on- Forecast A B year (after (B-A)/A revision) 2022年3月期 FY2021 19,933 Net sales 51,08
Slide 4: Breakdown of Net Sales (Consolidated)
Breakdown of Net Sales (Consolidated) （ Unit: million yen ） ◆Net sales 34,343 million yen FY2021 Year-on-year: (16,738) million FY2022 Reference yen (Apr. 1, 2021- (Apr. 1, 2022-Mar. 31, 2023) 2022年3月期 51,082 Mar. 31, 2022) FY2021 品目 Forecast グロウジェクト GROWJECT (683) Composition Composition Year-on-ye
Slide 5: Net Sales Trends by Product
Net Sales Trends by Product Recombinant therapeutic enzyme for (Unit: million yen) mucopolysaccharidosis 遺伝子組換えムコ多糖症II型酵素製剤 II (MPS II) Recombinant human growth hormone product GROWJECT® IZCARGO ® I.V. infusion 10mg イズカーゴ®点滴静注用10mg 1,262 1,059 1,070 1,047 1,047 12,650 13,256 12,945 957 12,261 761 NH
Slide 6: Net Sales Trends (Excluding AZD1222 Bulk Solution)
Net Sales Trends（Excluding AZD1222 Bulk Solution） (Unit: million yen) 製商品*売上高 Products* sales 契約金 License revenue * Products: GROWJECT, IZCARGO, treatment for renal anemia, TEMCELL, Agalsidase Beta BS I.V. Infusion [JCR], others 10,571 6,546 6,406 2,050 3,560 26,134 25,865 22,731 23,275 19,600 FY201
Slide 7: Financial Status (Consolidated)
Financial Status (Consolidated) （ Unit: million yen ） Change Change End-Mar. End-Mar. End-Mar. End-Mar. ・ Main ・ Main 2022 2023 2022 2023 Increase/decrease Increase/decrease Total (6,292) Total (14,385) ・ Income taxes payable ・ Cash and deposits Current 42,054 35,762 (5,881) (17,454) liabilities ・ S
Slide 8: Cash Flows (Consolidated)
Cash Flows (Consolidated) (Unit: million yen) FY2021 Ａ FY2022 B Year-on-year Ｂ-Ａ Income before income taxes 19,404 5,412 (13,991) Depreciation and amortization 1,945 1,997 +52 営業活動によるCF Operating Activities Decrease (increase) in trade receivables and accounts receivable – other (7,501) 3,269 +10,77
Slide 9: Forecast Highlights (FY2023)
Forecast Highlights (FY2023) Net sales： 36,900 million yen, Year-on-year +7.4% Operating income： 5,600 million yen, YoY +12.5% Ordinary income： 5,200 million yen, YoY (4.0)% Profit： 3,800 million yen, YoY +0.7% ■ Aim for solid increase in revenue by maintaining strong net sales of core products and
Slide 10: FY2023 Forecast (Consolidated)
FY2023 Forecast (Consolidated) （Unit: million yen） Supplemental information (YoY comparison) FY2022 FY2023 forecast Increase/ Impact on operating income (Apr. 1, 2022- (Apr. 1, 2023- Year-on-year Consolidated decrease • Increase in net sales Mar. 31, 2023) Mar. 31, 2024) (B-A)/A +2,556 million yen A
Slide 11: FY2023 Forecast (Consolidated)
FY2023 Forecast (Consolidated) （ Unit: million yen ） FY2022 FY2023 forecast (Apr. 1, 2022 - Mar. 31, 2023) (Apr. 1, 2023 - Mar. 31, 2024) Increase/ decrease Composition Composition Ｂ-Ａ Ａ ratio Ｂ ratio GROWJECT® 12,261 35.7% 10,900 29.5% (1,361) IZCARGO® 4,428 12.9% 5,200 14.1% ＋771 Treatments for re
Slide 12: IZCARGO Prescription Status
IZCARGO® Prescription Status 100 Net sales Cumulative cases (cases) Administered cases (cases) 売上高（百万円） (Unit: million yen) 累積症例数（例） 投与症例数（例） 74 77 80 71 67 59 60 60 45 62 64 57 60 60 56 40 43 17 20 761 1,059 957 1,070 1,047 1,262 1,047 224 0 FY2021 2021年度 FY2021 2021年度 FY2021 2021年度 FY2021 2021年度 F
Slide 13: Forward-Looking Statement
FORWARD-LOOKING STATEMENT This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All forward-looking statements regarding our plans, outlook, strategy and future performance are based on judgments derived
Slide 14: Copyright © 2023 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Copyright © 2023 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Slide 15: Reference: Trends in Sales Breakdown (Consolidated)
Reference: Trends in Sales Breakdown (Consolidated) 23,898 （単位：百万円） (Unit: million yen) 8,046 16,721 14,834 51 6,329 AZD1222 bulk AZD1222原液 11 53 404 0 Other 10,744 その他 51 License 契約金 Revenue 8,817 Agalsidase アガルシダーゼBeta BS ベータBS 1,931 56 14,712 TEMCELL テムセル 3,014 5,536 1,051 7,438 7,557 1,010 ダルベポエ
Slide 16: Reference: Trends in Composition Ratio of Cost/Expense
Reference: Trends in Composition Ratio of Cost/Expense Operating 営業利益 R&D 研究開発費 販売費・一般管理費 SG&A 売上原価 Cost of sales income expenses 20.5% 28.4% 26.0% 25.9% 31.9% 10,461 6,567 7,812 8,886 7,901 26.5% 28.7% 13,511 31.4% 34.0% 30.8% 8,643 7,270 11,678 7,638 14.0% 7,175 17.8% 18.8% 5,360 Above number (％)
Slide 17: Reference: Forecast of Net Sales Trends by Product
Reference: Forecast of Net Sales Trends by Product （Unit: million yen） Recombinant human growth hormone product Recombinant therapeutic enzyme for mucopolysaccharidosis II (MPS II) GROWJECT® IZCARGO® I.V. infusion 10mg 13,256 12,945 From April 24, 2023: Co-promotion with Sumitomo Pharma Co., Ltd. 12
Slide 18: Reference: Forecast of Net Sales Trends (Excluding AZD1222 Bulk Solution)
Reference: Forecast of Net Sales Trends (Excluding AZD1222 Bulk Solution) （ Unit: million yen ） 製商品*売上高 Products* sales 契約金 License revenue * Products: GROWJECT, IZCARGO, treatment for renal anemia, TEMCELL, Agalsidase Beta BS I.V. Infusion [JCR], others 10,571 8,100 6,546 6,406 2,050 26,134 25,865
Slide 19: Reference: Correlation between R&D Expenses and Main R&D Pipeline
Reference: Correlation between R&D Expenses (before Deducting) （ Unit: million yen ） Process development/ and Main R&D Pipeline 11,700 Non-clinical 9,480 7,671 Clinical trial 6,582 5,856 Filed an application Approved FY2019 2020年3月期 FY2020 2021年3月期 FY2021 2022年3月期 FY2022 2023年3月期 FY2023 (forecast) 2